Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mariantonia Nacchio, Pasquale Pisapia, Francesco Pepe, Gianluca Russo, Elena Vigliar, Tommaso Porcelli, Cristina Luongo, Antonino Iaccarino, Fabio Pagni, Domenico Salvatore, Giancarlo Troncone, Umberto Malapelle & Claudio Bellevicine. (2022) Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions. Expert Review of Endocrinology & Metabolism 17:2, pages 167-178.
Read now
Read now
Maria Grazia Borrello, Elena Ardini, Laura D Locati, Angela Greco, Lisa Licitra & Marco A Pierotti. (2013) RET inhibition: implications in cancer therapy. Expert Opinion on Therapeutic Targets 17:4, pages 403-419.
Read now
Read now
Articles from other publishers (24)
Angelina T. Regua, Mariana Najjar & Hui-Wen Lo. (2022) RET signaling pathway and RET inhibitors in human cancer. Frontiers in Oncology 12.
Crossref
Crossref
Poupak Fallahi, Silvia Martina Ferrari, Giusy Elia, Francesca Ragusa, Armando Patrizio, Sabrina Rosaria Paparo, Gianni Marone, Maria Rosaria Galdiero, Giovanni Guglielmi, Rudy Foddis, Alfonso Cristaudo & Alessandro Antonelli. (2022) Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. Seminars in Cancer Biology 79, pages 203-216.
Crossref
Crossref
Yuanyuan Liu, Shafei Wu, Liangrui Zhou, Yong Guo & Xuan Zeng. (2021)
Pitfalls in
RET
Fusion Detection Using Break-Apart FISH Probes in Papillary Thyroid Carcinoma
. The Journal of Clinical Endocrinology & Metabolism 106:4, pages e1129-e1138.
Crossref
Crossref
Yan Gu, Taosha Li, Anil Kapoor, Pierre Major & Damu Tang. (2020) Contactin 1: An Important and Emerging Oncogenic Protein Promoting Cancer Progression and Metastasis. Genes 11:8, pages 874.
Crossref
Crossref
Yuchen Jin, Min Liu, Ri Sa, Hao Fu, Lin Cheng & Libo Chen. (2020) Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics. Cancer Letters 469, pages 35-53.
Crossref
Crossref
Andrew Y. Li, Michael G. McCusker, Alessandro Russo, Katherine A. Scilla, Allison Gittens, Katherine Arensmeyer, Ranee Mehra, Vincenzo Adamo & Christian Rolfo. (2019) RET fusions in solid tumors. Cancer Treatment Reviews 81, pages 101911.
Crossref
Crossref
Silvia Martina Ferrari, Marco Centanni, Camilla Virili, Mario Miccoli, Paola Ferrari, Ilaria Ruffilli, Francesca Ragusa, Alessandro Antonelli & Poupak Fallahi. (2019) Sunitinib in the Treatment of Thyroid Cancer. Current Medicinal Chemistry 26:6, pages 963-972.
Crossref
Crossref
Sara Redaelli, Ivan Plaza-Menacho & Luca Mologni. (2018) Novel targeted therapeutics for MEN2. Endocrine-Related Cancer 25:2, pages T53-T68.
Crossref
Crossref
R. Nazari-Vanani, N. Azarpira, H. Heli, K. Karimian & N. Sattarahmady. (2017) A novel self-nanoemulsifying formulation for sunitinib: Evaluation of anticancer efficacy. Colloids and Surfaces B: Biointerfaces 160, pages 65-72.
Crossref
Crossref
Swapnil P. Bhujbal, Pavithra K. Balasubramanian & Seung Joo Cho. (2017) In silico studies on 2-substituted phenol quinazoline derivatives as RET receptor tyrosine kinase antagonists. Medicinal Chemistry Research 26:12, pages 3228-3239.
Crossref
Crossref
Ting-Hsuan Yang, Chun-I Lee, Wen-Hsin Huang & An-Rong Lee. (2017) Synthesis and Evaluation of Novel 2-Pyrrolidone-Fused (2-Oxoindolin-3-ylidene)methylpyrrole Derivatives as Potential Multi-Target Tyrosine Kinase Receptor Inhibitors. Molecules 22:6, pages 913.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
167
197
.
Silvia Martina Ferrari, Poupak Fallahi, Ugo Politti, Gabriele Materazzi, Enke Baldini, Salvatore Ulisse, Paolo Miccoli & Alessandro Antonelli. (2015) Molecular Targeted Therapies of Aggressive Thyroid Cancer. Frontiers in Endocrinology 6.
Crossref
Crossref
Jennifer A. Morrison, Laura A. Pike, Greg Lund, Qiong Zhou, Brittelle E. Kessler, Kevin T. Bauerle, Sharon B. Sams, Bryan R. Haugen & Rebecca E. Schweppe. (2015) Characterization of Thyroid Cancer Cell Lines in Murine Orthotopic and Intracardiac Metastasis Models. Hormones and Cancer 6:2-3, pages 87-99.
Crossref
Crossref
Omar Abdel-Rahman. (2015) Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): From bench to bedside. Critical Reviews in Oncology/Hematology 94:1, pages 45-54.
Crossref
Crossref
Poupak Fallahi, Valeria Mazzi, Roberto Vita, Silvia Ferrari, Gabriele Materazzi, David Galleri, Salvatore Benvenga, Paolo Miccoli & Alessandro Antonelli. (2015) New Therapies for Dedifferentiated Papillary Thyroid Cancer. International Journal of Molecular Sciences 16:12, pages 6153-6182.
Crossref
Crossref
Tianwei Zhang, Yachao Lu, Qingqing Ye, Meizhuo Zhang, Li Zheng, Xiaolu Yin, Paul Gavine, Zhongsheng Sun, Qunsheng Ji, Guanshan Zhu & Xinying Su. (2015)
An evaluation and recommendation of the optimal methodologies to detect
RET
gene rearrangements in papillary thyroid carcinoma
. Genes, Chromosomes and Cancer 54:3, pages 168-176.
Crossref
Crossref
Adebowale J. Adeniran. 2015. Molecular Oncology Testing for Solid Tumors. Molecular Oncology Testing for Solid Tumors
341
374
.
Vivek Subbiah, Funda Meric-Bernstam, Gordon B Mills, Kenna R Mills Shaw, Ann Marie Bailey, Priya Rao, John F Ward & Lance C Pagliaro. (2014) Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. Journal of Hematology & Oncology 7:1.
Crossref
Crossref
Chandra P Belani, Nobuyuki Yamamoto, Igor M Bondarenko, Artem Poltoratskiy, Silvia Novello, Jie Tang, Paul Bycott, Andreas G Niethammer, Antonella Ingrosso, Sinil Kim & Giorgio V Scagliotti. (2014) Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer 14:1.
Crossref
Crossref
Heounjeong Go, Yoo Jin Jung, Hyun Woong Kang, In-Kyu Park, Chang-Hyun Kang, Jung Wan Lee, Young Seok Ju, Jeong-Sun Seo, Doo Hyun Chung & Young Tae Kim. (2013) Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma. Lung Cancer 82:1, pages 44-50.
Crossref
Crossref
D. P. Modest, P. Camaj, V. Heinemann, B. Schwarz, A. Jung, R. P. Laubender, S. Gamba, C. Haertl, S. Stintzing, S. Primo & C. J. Bruns. (2013) KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. Journal of Cancer Research and Clinical Oncology 139:6, pages 953-961.
Crossref
Crossref
Anabel Sorolla, Andrée Yeramian, Joan Valls, Xavier Dolcet, Laura Bergadà, Antoni Llombart-Cussac, Rosa Maria Martí & Xavier Matias-Guiu. (2012) Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. Molecular Oncology 6:5, pages 530-541.
Crossref
Crossref
Annamaria Piscazzi, Eleonora Costantino, Francesca Maddalena, Maria Iole Natalicchio, Assunta Maria Teresa Gerardi, Raffaele Antonetti, Mauro Cignarelli & Matteo Landriscina. (2012) Activation of the RAS/RAF/ERK Signaling Pathway Contributes to Resistance to Sunitinib in Thyroid Carcinoma Cell Lines. The Journal of Clinical Endocrinology & Metabolism 97:6, pages E898-E906.
Crossref
Crossref